Zepos & Yannopoulos has advised Greek pharmaceutical technology start-up Purposeful on its collaboration with investor PharOS.
According to Zepos & Yannopoulos, PharOS is “making a significant investment in Greek start-up [Purposeful] and acquiring shares from existing shareholders, including Metavallon VC.”
PharOS is a Greek company developing generic pharmaceuticals and value-added medicines and commercializing their innovation in the healthcare industry. It was established in 2002.
According to the firm, “Purposeful aims to discover alternative uses for existing drugs using advanced artificial intelligence workflows, with a focus on finding therapies for rare diseases. During the last five years, the team has developed smart identification strategies for innovative pharmaceutical products targeting diseases like Fragile X Syndrome, Glioblastoma, Pitt-Hopkins Syndrome, and Acrodysostosis.”
The Zepos & Yannopoulos team included Senior Associate Stathis Orfanoudakis and Associates Artemis Bakagianni and Rania Koliouli.
Zepos & Yannopoulos did not respond to our inquiry on the matter.